share_log

Canaccord Genuity Maintains Hold on Oramed Pharmaceuticals, Lowers Price Target to $2

Benzinga ·  May 17, 2023 10:08

Canaccord Genuity analyst Edward Nash maintains Oramed Pharmaceuticals (NASDAQ:ORMP) with a Hold and lowers the price target from $3 to $2.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment